How Old is Too Old? Closure of Patent Foramen Ovale in Older Patients

Area of Science:

• Cardiology
• Neurology
• Vascular Medicine

Background:

• Patent Foramen Ovale (PFO) closure is proven to reduce recurrent cryptogenic stroke risk, primarily in younger patients.
• Key randomized controlled trials excluded individuals over 60, limiting evidence for PFO closure in older populations.
• Older adults often present with comorbidities that are independent stroke risk factors, complicating the assessment of PFO's role.

Purpose of the Study:

• To review the history and current evidence of PFO closure, with a specific focus on older adults.
• To discuss the challenges in evaluating and treating cryptogenic stroke in elderly patients with PFO.
• To highlight the need for further research and guidelines for this demographic.

Main Methods:

• Literature review focusing on studies of PFO closure and cryptogenic stroke.
• Analysis of existing randomized controlled trial data, noting exclusion criteria.
• Discussion of clinical considerations for older patients with PFO and stroke.

Main Results:

• PFO closure trials predominantly included younger patients, showing significant benefit.
• Data on the efficacy and safety of PFO closure in patients over 60 is scarce.
• Older patients with cryptogenic stroke and PFO are increasingly referred to cardiology, but lack specific management guidelines.

Conclusions:

• The benefit of PFO closure for recurrent cryptogenic stroke in older adults is not well-established.
• Further clinical trials are essential to guide the evaluation and treatment of PFO in the elderly population.
• Current practice requires careful consideration of individual risk factors and limited evidence in older patients.